drugset / Trial / NCT05177133
Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus)
Phase 2
Recruiting
25 enrolled
Academic Medical Center - University of Amsterdam
Incyte Corporation · collab
NaSingle-groupOpen-labelTreatment
Summary
To investigate the effects of the combination of two chemotherapies followed by immunostimulants on the interferon gamma expression and infiltration of cytotoxic T cells in the tumour microenvironment in patients with previously untreated metastatic or locally advanced esophagogastric cancer.
Timeline
- Start
- 2021-11-05
- Primary completion
- 2025-05-01
- Completion
- 2029-11-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Subject | Oxaliplatin | Small molecule | 130 mg/m2 | Intravenous |
| Subject | Retifanlimab | Monoclonal antibody | 500 mg | Intravenous |